Last reviewed · How we verify
M108 monoclonal antibody
M108 is a monoclonal antibody that targets a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or block pathogenic signaling.
At a glance
| Generic name | M108 monoclonal antibody |
|---|---|
| Sponsor | FutureGen Biopharmaceutical (Beijing) Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a monoclonal antibody in phase 3 development by FutureGen Biopharmaceutical, M108 is designed to modulate immune responses or directly target cancer cells. The exact molecular target and mechanism require further clarification from clinical trial data, but monoclonal antibodies in oncology typically work by blocking inhibitory signals on immune cells or directly engaging tumor antigens.
Approved indications
Common side effects
Key clinical trials
- A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer (PHASE3)
- M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. (PHASE3)
- Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M108 monoclonal antibody CI brief — competitive landscape report
- M108 monoclonal antibody updates RSS · CI watch RSS
- FutureGen Biopharmaceutical (Beijing) Co., Ltd portfolio CI